PSI Expands International Clinical Trial Presence to South Africa

Zug, Switzerland–Today, PSI CRO, a full-service contract research organization, announced their expansion into South Africa.

South Africa is a multi-cultural nation with a population of ~50 million people.  It has a long history of conducting clinical trials.  As such, there exists a strong infrastructure to support all needed activities including regulatory oversight and experienced researchers.  Data generated from South African trials receives international acceptance.    Expert opinion leaders work in South Africa, providing a high standard of medical care.  Therefore, patients who have received state-of-the-art therapy, in addition to treatment-naïve patients, may be recruited for clinical trials.  PSI will expand its access to all African countries from the strong base in Pretoria. PSI's current experience in South Africa stretches across the areas of oncology, CNS, urology, diabetes and other therapeutic areas.

About PSI CRO AG:  PSI is a privately held, full-service contract research organization (CRO), operating globally.  PSI positions itself as a no-nonsense CRO capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines.  PSI's global reach supports the operations of clinical trials across multiple countries and continents.  PSI has exceptionally high repeat and referral business rates that are indicative of a commitment to be the best CRO in the world as measured by clients and employees.  Global headquarters are located in Zug, Switzerland at 113a Baarerstrasse 6300.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.